Clinical trials: Leukemia Acute Myeloid - AML
Leukemia, Myeloid, Acute
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.
- Trial name
- NCT01468467
- Testing
- AC220
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Daiichi Sankyo
Acute Myeloid Leukemia
A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Mylotarg) for the potential treatment of acute myeloid leukemia (AML).
- Trial name
- NCT05189639
- Where
- South Korea
- Volunteers
- 165 people
- Sponsor
- Pfizer
AML, MDS
A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
This is a Phase 1/2a dose-escalation study of E6201, a dual mitogen-activated protein kinase/extracellular-signal regulated kinase 1 (MEK1) and FMS-like tyrosine kinase 3 (FLT3) inhibitor, in subjects with advanced hematologic…
- Conditions
- AML, MDS, CMML
- Trial name
- NCT02418000
- Testing
- E6201
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spirita Oncology, LLC
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00083187
- Testing
- hydroxyurea, laromustine
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 230 people
- Sponsor
- Vion Pharmaceuticals
AML, CMML
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
A Phase 1/2a Dose Escalation Study of FF-10501-01 in Patients with Relapsed or Refractory Hematological Malignancies to determine the safety and tolerability. A total of 6 cohorts will be enrolled in Phase 1 to establish the MTD.
- Conditions
- AML, CMML, MDS
- Trial name
- NCT02193958
- Testing
- FF-10501-01
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Relapsed/Refractory AML, AML, Adult
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory…
- Conditions
- Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
- Trial name
- NCT04623944
- Testing
- NKX101 - CAR NK cell therapy
- Where
- 8 sites in United States
- Volunteers
- 61 people
- Sponsor
- Nkarta, Inc.
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission…
- Trial name
- NCT03070093
- Testing
- gilteritinib
- Where
- 39 sites in United States, Canada and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this…
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
- Trial name
- NCT06563804
- Testing
- S227928, Venetoclax
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 13 people
- Sponsor
- Servier Bio-Innovation LLC
Acute Myeloid Leukaemia
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
- Trial name
- NCT07036250
- Testing
- U32 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Leukemia, Acute Myeloid Leukemia
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
This is a single-arm, single-dose dose-escalation and dose-expansion study.
- Trial name
- NCT06347458
- Testing
- BG1805
- Volunteers
- 24 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Cancer - Acute Myeloid Leukemia
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or…
- Trial name
- NCT03484520
- Testing
- Venetoclax, Dinaciclib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 48 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients
Patients will receive oral SKLB1028 for 28 days as a course of treatment, and then to evaluate the side effects,tolerability and best dose for treating relapsed or refractory acute myeloid leukemia With FLT3 Mutations.
- Trial name
- NCT04015024
- Testing
- SKLB1028 150mg bid, SKLB1028 200mg bid, SKLB1028 300mg qd
- Where
- China
- Volunteers
- 30 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Acute Myeloid Leukemia
Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to determine the effectiveness of tipifarnib in patients aged 70 or more with acute myeloid leukemia. Tipifarnib belongs to a class of drugs called Farnesyl Transferase Inhibitors (FTI).
- Trial name
- NCT00093990
- Testing
- Tipifarnib;Zarnestra; R115777
- Volunteers
- 457 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hematologic Malignancy, Non Hodgkin Lymphoma
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological…
- Conditions
- Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult
- Trial name
- NCT06206174
- Testing
- TGRX-814
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Leukemia, Myeloid, Acute
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication ( FLT3-ITD) positive.
- Trial name
- NCT01565668
- Testing
- AC220
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 76 people
- Sponsor
- Daiichi Sankyo
B-cell Lymphoma, Chronic Lymphocytic Leukemia
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of patients who participated in an AvenCell-sponsored clinical trial and received treatment with AvenCell's UniCAR or…
- Conditions
- B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
- Trial name
- PERSIST (NCT07474051)
- Testing
- UniCAR02-T (IMP) With Targeting Module TM123, UniCAR02-T-pPSMA, Allo-RevCAR01- T with Targeting Module R-TM123
- Where
- 5 sites in Germany
- Volunteers
- 178 people
- Sponsor
- AvenCell Therapeutics, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma
- Trial name
- RACE (NCT00761722)
- Testing
- azacitidine
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with…
- Trial name
- NCT06146257
- Testing
- GLB-001
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- GluBio Therapeutics Inc.
AML M4, AML M5
Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)
This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).
- Trial name
- NCT04803929
- Testing
- anti-ILT3 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Carbiogene Therapeutics Co. Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03802695
- Testing
- OrcaGraft (Orca-Q)
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orca Biosystems, Inc.